Moderna (MRNA) Tops Q2 EPS by 70c, Beats on Revenue

Moderna (NASDAQ: MRNA) reported Q2 EPS of $5.24, $0.70 better than the analyst estimate of $4.54. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.07 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'